I think it's great that they have a drug for Fabry disease on the market, but I'm already betting on the corresponding genetic engineering disruptor in the portfolio, primarily with regard to this disease. I believe my stock has extreme potential in the future, it is in a top scientific position for R+D, recently reached a promising agreement with the FDA, and I am currently staying on board. Basically, however, this is an absolutely interesting stock that you have presented here, the current and future financial development is definitely not uninteresting.👌🏻 Thanks for this, I'll put it on my watch.
•
77
•
@All-in-or-nothing
I think there is potential. The key figures are right.
I think there is potential. The key figures are right.
•
11
•
10Mes
@All-in-or-nothing Which one do you have there?
•
11
•@Multibagger $SGMO as a genetic engineering value. In my view, this method is much more suitable for mass production than, for example, editing with Crispr (because Crispr is irreparable and therefore much more far-reaching). Sangamo's current focus is on Fabry disease, but I think there's a lot more that could be done. There were a few good articles about it here on the platform, and that, plus my own research, tipped the scales in my favor.
•
33
•